A practical reference on mass spectrometry: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-12. Anything still debated is marked as such rather than presented as settled.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Where b is binding rate, and k is processing rate. Since the dissociation rate of the substrate-SU complex to (unchanged) substrate and (unbounded) SU is assumed to be small, d θ . d t {\displaystyle {\frac {d\theta _{.}}{dt}}} and d θ S d t {\displaystyle {\frac {d\theta _{S}}{dt}}} are assumed to be zero. This system of equation suggests the free SU percentage is θ . = k b S + k {\displaystyle \theta _{.}={\frac {k}{bS+k}}} and the product of flux is J p = k S S + S / b {\displaystyle J_{p}={\frac {kS}{S+S/b}}} The first modification is an extension of the classic theory; if arrival fluxes are taken proportional to substrate concentrations, the classic theory results. This extension allows application in spatially heterogeneous environments (such as in living cells), and to treat photons and molecules in the same framework (important in photosynthesis).
== Osmium isotopes in radiometric dating == The isotopic ratio of osmium-187 and osmium-188 (187Os/188Os) can be used as a window into geochemical changes throughout the ocean's history. The average marine 187Os/188Os ratio in oceans is 1.06. This value represents a balance of the continental riverine inputs of Os with a 187Os/188Os ratio of ~1.3, and the mantle/extraterrestrial inputs with a 187Os/188Os ratio of ~0.13. The lighter isotope, 187Os, is produced by beta decay of 187Re. This decay has actually increased the 187Os/188Os ratio of the bulk silicate earth (Earth less the core) by 33%. The difference between crust and mantle ratios is explained this way: crustal rocks have a much higher level of rhenium. Re is concentrated in the crust relative to the mantle due to partial melting of the mantle (differentiation). Because Re is partitioned into the melt more than other PGEs, it increases in the crust over time.}, which produces an excess of 187Os. The combined input of the two sources to the marine environment results in the observed ratio in the oceans, and has fluctuated over the geologic history. These changes in the isotopic values of marine Os can be observed in the marine sediment that is deposited, and eventually lithified in that time period. This allows for researchers to estimate weathering fluxes, flood basalt volcanism, and impact events that may have caused some of our largest mass extinctions. The marine sediment Os isotope record has corroborated the K-T boundary impact, for example.
Researchers report in a preprint the CRISPR alternative fanzor naturally present in eukaryotes with several potential advantages over CRISPR in genome editing, notably smaller size and higher selectiveness. A separate team further demonstrates in a preprint (14 June) the potential of this class of genome editors. 29 June – Astronomers report using a new technique to detect, for the first time, the release of neutrinos from the galactic plane of the Milky Way galaxy. Hazard research is published: study results suggest high-temperature cooking could cause DNA damage within food (especially meat) which in turn could cause human DNA damage (1 June), a study concludes the Italian Phlegraean Fields could be heading towards a first eruption since 1538 (9 June), a small team of researchers evaluates the credibility of net-zero climate targets as currently low (9 June), an AHA review shows that exposure to contaminant metals contributes to cardiovascular diseases (12 June), a study in the context of the opioid epidemic shows males are substantially (2–3 times greater) more vulnerable to or affected by drug overdose mortality than females (15 June), loss of Y chromosome can drive cancer growth (21 June), a study indicates nearly 40% of U.S.
Since independence, Ghana has been devoted to ideals of nonalignment and is a founding member of the Non-Aligned Movement. Ghana favours international and regional political and economic co-operation, and is an active member of the United Nations and the African Union. Three U.S. presidents have made diplomatic trips to Ghana (Bill Clinton, George W. Bush and Barack Obama), along with a Vice President (Kamala Harris). Some Ghanaian diplomats and politicians hold positions in international organisations, including Ghanaian diplomat and former Secretary-General of the United Nations Kofi Annan, International Criminal Court Judge Akua Kuenyehia, and former President Jerry John Rawlings and former President John Agyekum Kufuor, who both served as diplomats of the United Nations. In September 2010, President John Atta Mills visited China on an official visit. Mills and then-general secretary of the Chinese Communist Party Hu Jintao marked the 50th anniversary of diplomatic ties between the two nations, at the Great Hall of the People. China reciprocated with an official visit in November 2011, by the vice-chairman of the Standing Committee of the National People's Congress of China, Zhou Tienong who visited Ghana and met with Ghana's president John Mahama. China became one of the top investing countries of Ghana, which predominantly focus on infrastructure, natural resources, and the manufacturing sector, have promoted economic growth, job creation, and technology transfer in Ghana.
Sources: en.wikipedia.org
== Mechanism of action == Precise mechanism of antidepressant activity of SSRIs remains somewhat uncertain, but a number of biochemical functions associated with SSRI treatment have been established. SSRIs primarily inhibit SERT in the brain and have negligible effects on DAT and NET. The SSRIs also have less affinity for α1, α2, H1 and muscarinic receptors, which might explain the differences of adverse events between TCAs and SSRIs. Although SSRIs arrive rapidly to the brain after administration and the effects on 5-HT re-uptake can be measured instantly, it takes about 2–4 weeks to get therapeutic effects. The SSRIs have very high and selective affinity for SERT and after administration they inhibit SERT immediately. SERT inhibition is implicated in the antidepressant activity of SSRIs. 70-80% inhibition of SERT is usually necessary to induce antidepressant effects and higher dosage does not induce greater antidepressant effects for average patients. Higher dosage does, however, increase the incidence and severity of adverse events associated with excessive 5-HT re-uptake inhibition.
Vecuronium and pancuronium have an onset of 2 to 5 minutes in adults. The time it takes to recover 25% of neuromuscular control after vecuronium and pancuronium therapy are 25 to 40 minutes and 60 to 80 minutes respectively. Acetylcholinesterase inhibitor
The account, which repeatedly used racial slurs and claimed that the adult animated series South Park and Family Guy would appear on Disney Junior, was suspended after Disney found the account. The removal of blue checkmarks has had a political impact. Taking advantage of the removal of the blue checkmarks for the Twitter accounts for Chicago mayor Lori Lightfoot, the Chicago Department of Transportation, and the Illinois Department of Transportation, false accounts began appearing claiming that the major expressway Lake Shore Drive would close next month for private traffic. Similarly, an impostor account appeared after the New York City Government account tweeted that it was official. New York representative Alexandria Ocasio-Cortez warned of potential harm in misinformation after the encounter. At least eleven accounts claiming to be the Los Angeles Police Department appeared in the wake of the removal of blue checkmarks. An account claiming to be New York City mayor Eric Adams promised to create a Department of Traffic and Parking Enforcement while slashing funding for the New York City Police Department; the operator of the account was later discovered to be Josh Boerman, co-host of the podcast The Worst of All Possible Worlds, who claimed to have made the account in jest. Election offices for four of the most populous counties in the United States—Cook County, Illinois, Harris County, Texas, Maricopa County, Arizona, and San Diego County, California—were unverified.
Sources: en.wikipedia.org
Network Science, Part 5: Solvent-Accessible Surfaces AREAIMOL is a command line tool in the CCP4 Program Suite for calculating ASA. NACCESS solvent accessible area calculations. FreeSASA Open source command line tool, C library and Python module for calculating ASA. Surface Racer Oleg Tsodikov's Surface Racer program. Solvent accessible and molecular surface area and average curvature calculation. Free for academic use. ASA.py — a Python-based implementation of the Shrake-Rupley algorithm. Michel Sanner's Molecular Surface – the fastest program to calculate the excluded surface. pov4grasp render molecular surfaces. Molecular Surface Package — Michael Connolly's program. Volume Voxelator — A web-based tool to generate excluded surfaces. ASV freeware Analytical calculation of the volume and surface of the union of n spheres (Monte-Carlo calculation also provided). Vorlume Computing Surface Area and Volume of a Family of 3D Balls. GetArea Calculate solvent accessible surface area of proteins online. ProMS ProMS - Protein Molecular Surface Calculator
The classic Monod–Wyman–Changeux model (MWC) for cooperativity is generally published in an irreversible form. That is, there are no product terms in the rate equation which can be problematic for those wishing to build metabolic models since there are no product inhibition terms. However, a series of publications by Popova and Sel'kov derived the MWC rate equation for the reversible, multi-substrate, multi-product reaction. The same problem applies to the classic Hill equation which is almost always shown in an irreversible form. Hofmeyr and Cornish-Bowden first published the reversible form of the Hill equation. The equation has since been discussed elsewhere and the model has also been used in a number of kinetic models such as a model of Phosphofructokinase and Glycolytic Oscillations in the Pancreatic β-cells or a model of a glucose-xylose co-utilizing S. cerevisiae strain. The model has also been discussed in modern enzyme kinetics textbooks.
=== 1994 Tammiku, Estonia === The 1994 Tammiku incident involved the theft of radioactive material from a nuclear waste storage facility in Männiku, Saku Parish, Harju County, Estonia. Three brothers, unaware of the facility's nature, broke into a shed while scavenging for scrap metal. One of the brothers received a 4000 rad (40 Gy) whole-body dose from a caesium-137 source that had been released from a damaged container, succumbing to radiation poisoning 12 days later.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.